Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus (START)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00687284

NN304-3515

Details and patient eligibility

About

This study is conducted in Europe. An observational study evaluating glycaemic control in patients using Levemir® as initiation insulin therapy as the treatment of type 2 diabetes in Slovakia.

Enrollment: 2,188 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes
• Patients inadequately controlled by OAD
• Patients willing to sign informed consent
• Selection of study participants at the discretion of the physician
• Particular attention should be paid to the drug interactions that are listed within the product label

Exclusion criteria

• Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit;
• Subjects who were previously enrolled in this study
• Subjects with a hypersensitivity to insulin detemir or to any of the excipients.
• Women who are pregnant, breastfeeding or have the intention of becoming pregnant within next 6 months

Trial design

2,188 participants in 1 patient group

A

Treatment:

Drug: insulin detemir